NewGenPharm Inc.   Report issue

For profit Phase 2
Founded: Seoul Korea, Republic of (1992)
Status: No NME R&D (1992)

Organization Overview

First Clinical Trial
2016
NCT02894944
First Marketed Drug
2019
loratadine (claritin)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

NewGenPharm Incoporation | NEWGEN PHARMS LLC

Active Ingredients

Marketed Drugs (1)

loratadine (claritin) (2019)

Drugs in Phase 2 Trials (1)

ad5-ycd/muttksr39rep-adp (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Pancreatic Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1